

Meeting of the UNMMG Board of Directors Wednesday, August 8, 2018

8:00 – 10:00 a.m. Domenici West – Room 3010 1001 Stanford N.E. Albuquerque, New Mexico

Agenda

Item	Description of Agenda Item	Time (in minutes)
I.	Call to Order and Confirmation of Quorum (Michael Richards, M.D.)	1
II.	Opening Comments (Michael Richards, M.D.)	1
III.	Recognitions (Marjorie Goldstein)	5
IV.	Vote to Approve Minutes of the June 13, 2018 UNMMG Board of Directors Meeting (Michael Richards, M.D.) (ACTION)	2
V.	Public Comment	1
VI.	Report from Audit & Compliance Committee (Chris Pacheco) None	1
VII.	 Report from Finance Committee (Martha McGrew, M.D.) Acceptance of the Finance Committee Meeting Minutes (ACTION) <u>August 1, 2018</u> <u>Revenue Cycle Update</u> (JP Montoya) (INFORMATION) Collections per wRVU <u>June 2018 Financial Highlights</u> (Marjorie Goldstein) (ACTION) 	20
VIII.	Report from Operations Committee <i>Update (Gary Mlady, M.D.)</i> Acceptance of Operations Committee Meeting Minutes (ACTION) o June 20, 2018 o July 18, 2018	10

IX.	Clinic Operations Update (<i>Rebecca Ruddell</i>) (INFORMATION) a. <u>FY18 Results</u>	15
IX.	 Chief Executive Officer Report (<i>Marjorie Goldstein & Rebecca Ruddell</i>) (ACTION) <u>FY18 Big 8 Preliminary Results</u> FY19 Big 8 Components 	15
X.	Interim Chief Medical Officer Report - <i>None (Michael Richards, M.D.)</i> <u>Clinical Policies & Procedures (ACTION)</u> <u>Clinical Privileges (ACTION)</u> 	10
XI.	Board Chair Report - (Michael Richards, M.D.)	1
XII.	Physician Advisory Group Report (Melissa Ivers, D.M.D.) (ACTION)	5
XIII.	 Vote to go into Executive Session for the following purposes (<i>Michael Richards</i>, <i>M.D.</i>) a. Discussion and, where appropriate, determination of matters involving information, proceedings, or actions covered by the confidentiality protections of the New Mexico Review Organization Immunity Act, § 41-91-1 et seq., NMSA 1978, as provided in Section 5(10) of the UNMMG's Open Meetings Policy. b. Portions of meetings of the Board of Directors where strategic and long-range business plans, trade secrets, or institutional compliance program matters are discussed. 	30
XIV.	 Vote to Reconvene in Open Session (<i>Michael Richards, M.D.</i>): a. Certification that only those matters described in Agenda Item 14 above were discussed in Executive Session and, if necessary, final action with regard to those matters will be taken in Open Session. 	1
XV.	Vote to Adjourn (Michael Richards, M.D.)	1